Analyst Charles Rhyee of TD Cowen maintained a Buy rating on Cencora (COR – Research Report), with a price target of $288.00. Charles ...

In a report released yesterday, Steve Baxter from Wells Fargo maintained a Hold rating on Cencora (COR – Research Report), with a price ...

Cencora, Inc. is a pharmaceutical sourcing and ... The U.S. Healthcare Solutions segment focuses on the distribution of specialty, brand-name, and generic pharmaceuticals. The International ...

Cencora, Inc. (NYSE: COR) today reported that in its fiscal year 2024 fourth quarter ended September 30, 2024, revenue increased 14.7 percent to $79.1 ...

Cencora, Inc. COR is well-poised for growth ... the introduction of innovative drugs like hepatitis C treatments and a strong brand pricing environment are expected to contribute positively.

The likely GOP sweep of the House, Senate and White House has dampened expectations for health care policy riding in a lame-duck package.

It has been about a month since the last earnings report for Walgreens Boots Alliance (WBA). Shares have lost about 18.4% in that time frame, underperforming the S&P 500. Will the recent negative ...

COR continues to gain traction from the robust U.S. Healthcare Solutions segment. However, stiff competition is a woe.

Gains from antitrust litigation settlements relate to the settlement of lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the manufacturer, by itself or in ...